Unicycive Therapeutics
Develops kidney-disease candidates for dialysis and acute injury.
Something off on this page? Send us feedback.
Profile
Develops two in-licensed renal-disease candidates: OLC, an oral phosphate binder for hyperphosphatemia in dialysis patients, and UNI-494 for acute-kidney-injury-related conditions. The pre-commercial business depends on advancing these programs, FDA action, and third-party manufacturing readiness.
Develops two in-licensed candidates for kidney disease: oxylanthanum carbonate (OLC) for hyperphosphatemia in dialysis patients and UNI-494 for conditions related to acute kidney injury.
OLC is an investigational oral phosphate binder. Its resubmitted new drug application received a second Complete Response Letter tied to third-party manufacturing deficiencies; FDA did not cite clinical efficacy or safety concerns or request additional data.
UNI-494 has orphan-drug designation for preventing delayed graft function in kidney-transplant patients and has completed an early safety study. As a pre-commercial business, development work, FDA action, and third-party manufacturing readiness shape its operating path.
Company facts
Key statistics
Year to date −9.3% · Average volume (30d) 754.0K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| May 27, 2026 | H.C. Wainwright | Target | $22 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.47 | −$0.06 | +87.3% | $22.2M | — | — | +0.19% |
| Aug 12, 2026Q2 FY26 | −$0.47 | −$0.06 | +87.3% | $22.2M | — | — | +7.80% |
| May 12, 2026Q1 FY26 | −$0.55 | −$0.54 | +1.8% | $11.1M | — | — | +4.16% |
| Mar 30, 2026Q4 FY25 | −$0.50 | −$0.32 | +36.6% | $517.0K | — | — | +7.69% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$211.0K | $0 | |
| Operating income | −$8.0M | −$7.0M | −$7.3M | −$7.2M | −$8.4M | −$10.1M | |
| Net income | $570.0K | −$6.4M | −$6.0M | −$14.7M | −$12.8M | −$1.7M | |
| Diluted EPS | −$0.50 | −$0.52 | −$0.33 | −$0.74 | −$0.54 | −$0.06 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $951.0K · FY23 $675.0K · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $61.4M · Total debt $671.0K · Total assets $72.0M · Shareholders' equity $53.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 26.70M · Float 24.28M · 90.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 6.10M | 9.99% | 13G | Nov 14, 2025 |
| RA Capital Management, L.P. | 2.80M | 9.90% | 13G | May 15, 2026 |
| Vivo Capital, LLC | 1.79M | 6.70% | 13F | May 20, 2026 |
| Gaurav Aggarwal · director | 1.79M | 6.70% | Form 4 | Aug 26, 2025 |
| BlackRock, Inc. | 1.41M | 5.30% | 13G | Jul 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Ardelyx
XPHOZAH is an approved phosphate absorption inhibitor for dialysis
- Fresenius Medical Care (ADR)
Velphoro is an iron-based phosphate binder for dialysis
- Akebia Therapeutics
Auryxia controls serum phosphorus in adults on dialysis
- Sanofi (ADR)
Renvela and Renagel are established dialysis phosphate binders
- Takeda (ADR)
Fosrenol is a lanthanum carbonate phosphate binder
- OPKO Health
Alpharen is a development-stage potential phosphate-binder entrant
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Unicycive Therapeutics | $5.32 | +1.14% | $140.6M | — | — | — | — |
| Ardelyx | $3.84 | +0.75% | $941.2M | — | — | 2.1 | +23.8% |
| Fresenius Medical Care (ADR) | $23.10 | +0.13% | $12.41B | 11.9 | 16.7 | 0.5 | −0.7% |
| Akebia Therapeutics | $0.8897 | +1.13% | $235.7M | — | — | 1.1 | −21.4% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| Takeda (ADR) | $18.49 | +2.53% | $57.37B | 51.0 | 53.7 | 2.0 | +5.8% |
| OPKO Health | $1.46 | −1.68% | $1.10B | — | — | 1.9 | +4.3% |
| Median | 51.0 | 35.2 | 1.9 | +5.0% |